Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about US$3.2 billion in a move to strengthen its position on central nervous system condition treatments.
Jerusalem-based Teva said Monday that it will pay US$101 per share, marking a 47% premium to San Diego-based Auspex’s closing stock price on Friday.
Read: Valeant raises bid for Salix
Auspex does not yet have a product on the market. Its lead product candidate is Austedo, which is aimed at treating involuntary movement associated with the genetic disorder Huntington’s disease.
Teva is one of the world’s largest generic drug developers. It also has a range of specialty medicines, including Copaxone for multiple sclerosis and Azilect for Parkinson’s disease. Revenue in 2014 reached US$20.3 billion.
Read: AbbVie to pay US$21 billion for Pharmacyclics
“The acquisition of Auspex is a significant step in strengthening Teva’s leadership position in central nervous system (disorders) and advances us into underserved movement disorder markets,” says Teva president and CEO Erez Vigodman.
Teva expects the buyout of Auspex to start contributing revenue in 2016 with an anticipated launch of Auspex.
The acquisition is expected to close in mid-2015.
Also read: